Family · Pharmaceutical analytical standards
Carfilzomib
A second-generation proteasome inhibitor that binds its target irreversibly: approved in the United States in 2012 for relapsed multiple myeloma. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It derives from epoxomicin, a molecule produced by an actinomycete and described in 1992 as an antitumour agent: in 1999 Craig Crews's laboratory at Yale showed that its target is the proteasome.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
